Contineum Therapeutics (CTNM) Return on Sales (2023 - 2024)
Contineum Therapeutics (CTNM) recorded quarterly Return on Sales of 0.01% in Q2 2024, down 175.63% quarter-over-quarter from 0.01% in Q2 2023, and down 1.0% on a YoY basis from 0.01% in Q3 2023.
Contineum Therapeutics (CTNM) Return on Sales (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Return on Sales history runs 2 years deep, the most recent figure standing at 0.01% for Q2 2024.
- In Q2 2024, Return on Sales fell 1.0% year-over-year to 0.01%; the TTM figure through Jun 2024 stood at 0.01% (changed N/A YoY), while the FY2023 annual figure was 0.0%, changed N/A from the prior year.
- Return on Sales was 0.01% for Q2 2024 at Contineum Therapeutics, down from 0.01% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.01% in Q2 2023 to a low of 0.01% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.00% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 0.00% |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.01% |
| Jun 30, 2023 | 0.01% |